Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) - Equities researchers at Brookline Capital Management lifted their Q2 2025 earnings per share estimates for shares of Verrica Pharmaceuticals in a note issued to investors on Wednesday, May 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.08). The consensus estimate for Verrica Pharmaceuticals' current full-year earnings is ($1.46) per share. Brookline Capital Management also issued estimates for Verrica Pharmaceuticals' Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.26) EPS.
A number of other equities research analysts have also recently commented on the stock. Wall Street Zen raised shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Needham & Company LLC reiterated a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "neutral" rating on shares of Verrica Pharmaceuticals in a report on Tuesday, April 8th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Verrica Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $8.00.
Read Our Latest Analysis on VRCA
Verrica Pharmaceuticals Stock Performance
NASDAQ VRCA traded down $0.01 during trading hours on Monday, reaching $0.61. The company's stock had a trading volume of 112,041 shares, compared to its average volume of 580,952. The stock has a market cap of $56.58 million, a PE ratio of -0.33 and a beta of 1.73. Verrica Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $9.36. The company's 50-day moving average is $0.51 and its two-hundred day moving average is $0.68.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. The company had revenue of $3.44 million for the quarter, compared to analyst estimates of $2.53 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%.
Institutional Investors Weigh In On Verrica Pharmaceuticals
Several hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of Verrica Pharmaceuticals by 23.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock worth $61,000 after purchasing an additional 26,308 shares during the last quarter. AQR Capital Management LLC boosted its position in Verrica Pharmaceuticals by 306.7% during the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after acquiring an additional 44,275 shares during the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in Verrica Pharmaceuticals during the first quarter worth approximately $45,000. Invesco Ltd. boosted its holdings in shares of Verrica Pharmaceuticals by 64.8% during the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock worth $33,000 after purchasing an additional 29,256 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Verrica Pharmaceuticals by 127.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company's stock worth $44,000 after purchasing an additional 55,852 shares during the last quarter. 42.45% of the stock is owned by institutional investors and hedge funds.
Verrica Pharmaceuticals Company Profile
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Recommended Stories
Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
